Clinical Trial Update: PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of panitumumab in combination with gemcitabine and cisplatin for advanced urothelial (bladder) cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Panitumumab (panitumumab)

Snippet

Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH | Conditions: Urinary Bladder Cancer | Phase 2 | Status: TERMINATED